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Background. The World Health Organization (WHO) recently recommended 2-dose primary rabies immunization instead of the 3-dose standard regimen. Given limited data of 2-dose regimens in pediatric population, this study was conducted. The objective was to compare the immunogenicity between 2-dose and 3-dose primary rabies immunization.
Methods. This study was an open-label clinical trial. Inclusion criteria were children aged 2-12 years with rabies virus neutralizing antibody (RVNA) titers < 0.5 IU/ ml at baseline. The participants were divided into 2-dose vaccination (2D) on days 0 and 28 and 3-dose vaccination (3D) on days 0, 7, and 28 with a 2:1 ratio. A dose of 0.5 ml purified vero cell rabies vaccine (PVRV) was administered intramuscularly. RVNA titers were measured at 14-day post primary immunization. RVNA titers ≥ 0.5 IU/ml were considered seroprotective against rabies. Geometric mean titers (GMT) were calculated. T cell specific response to rabies vaccine antigen were measured from peripheral blood mononuclear cells (PBMCs) using the interferon-gamma enzymelinked immunospot (IFN-gamma ELISpot) assay.
Results. From September to October 2017, 105 participants (52% male), 76 in 2D group and 29 in 3D group were enrolled. Median age and body weight was 70 months (IQR 53-88) and 19.2 kilograms (IQR 15.9-24.3), respectively. All participants had seroprotection at 14-day post primary immunization with GMT of 18.6 (95% CI 15.8-21.9) and 16.3 (95% CI 13.1-20.0) in 2D and 3D groups, respectively (P = 0.35). Median IFN-gamma level at 14-day post primary immunization was 60 spot forming cells (SFC) per 10 6 PBMCs and 132 SFC per 10 6 PBMCs in the 2D and 3D groups, respectively (P = 0.15).
Conclusion. The immunogenicity of 2-dose primary rabies immunization at 14-day post primary vaccination is comparable to the 3-dose regimen. Participants are currently being followed for 1-year results.
Disclosures. Background. Antibiotic exposure around the time of rotavirus (RV) immunization has been suggested to diminish immune responses, but data are sparse.
Methods. We retrospectively analyzed data from a randomized RV vaccine study (NCT01266850) outlined in the Table. Concomitant antibiotic use, defined as receipt of an antibiotic 14 days before or 7 days after RV immunization, was recorded. The primary outcome was RV-specific IgA seroresponse (IgA ≥20 U/mL) by ELISA obtained 1 month after the last dose of RV vaccine and geometric mean titer (GMT) to strain WC3 (RV5 backbone) or strain 89-12 (RV1 backbone). Only subjects who received all scheduled vaccine doses and phlebotomy were included. Data were assessed for homogeneity across vaccine schedule groups, stratified by antibiotic exposure. We examined differences in seroresponse adjusting for treatment group, gender, race, ethnicity, and study site using logistic regression models.
Results. Of the 1384 immunized children, 1174 (85%) met inclusion criteria. Nearly 10% (n = 114) of participants were antibiotic exposed; group 4 had the least antibiotic exposure (P = 0.05). No differences in GMT or seroresponses were observed to either WC3 or 89-12 (figure) by antibiotic exposure. In the multivariable logistic regression model, there were no significant differences for gender, race, ethnicity, site, or antibiotic exposure (P-value ≥0.5 for IgA seroresponse). The only observed difference in seroresponses was by RV vaccine group (P < 0.0001).
Conclusion. Antibiotic administration around the time of RV vaccine did not diminish RV-specific IgA seroresponses observed 1 month after the last RV vaccine dose.
